history of glp 1 drugs GLP-1 Market Size to Hit USD 132.79 Bn by 2035 Timeline of critical milestones in
Description
Insurance companies therefore either elect to exclude GLP-1 drugs from their drug formulary, or create barriers to accessing them
Top Key Players Novo Nordisk A/S Eli Lilly and Company Hoffmann-La Roche AG Pfizer Inc
In a randomized controlled trial (RCT) evaluating the weight change using semaglutide, it was also found that after discontinuation of semaglutide, the patients gained weight significantly as well as a significant increase in blood pressure [17], which was a reminder that weight regain may have some adverse effects
Recent research suggests that GLP-1 drugs may have promise in the treatment of cardiovascular disease, neurodegenerative disorders, and drug and alcohol addiction, among others
There's little evidence that GLP-1 patches work at all, let alone better than clinically approved weight loss injections
